Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years

Novavax, Inc. announced the initiation of its Phase IIb/III Hummingbird global clinical trial. The trial will evaluate the safety, effectiveness, and efficacy of two doses of the Novavax COVID-19 vaccine in younger children aged six months through 11 years, followed by a booster at six months after the primary vaccination series.
[Novavax, Inc.]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News